PubMed چکیده/رکورد

Strengthening Spontaneous Adverse Drug Reaction Reporting in Vietnamese Provincial Hospitals: A Multicenter Clinical Pharmacy-Led Multifaceted Intervention.

استودیوی صوتی مقاله

پخش حرفه‌ای فارسی و انگلیسی

در حال بررسی نسخه‌های صوتی ذخیره‌شده…

صوت تولیدشده با هوش مصنوعی است. برای کاربرد علمی یا درمانی، متن و منبع اصلی را بررسی کنید.
خواندن هوشمند فارسی و انگلیسی در حال آماده‌سازی صداهای مرورگر…
تنظیم صدای طبیعی و سرعت

صداهایی که در نامشان «Natural»، «Neural» یا «Online» دیده می‌شود معمولاً طبیعی‌ترند. انتخاب صدا به صداهای نصب‌شده در ویندوز و مرورگر شما بستگی دارد.

چکیده اصلی

BACKGROUND: Under-reporting of adverse drug reactions (ADRs) limits medication-safety learning in provincial hospitals, where dedicated pharmacovigilance infrastructure and personnel are often constrained. The objective of this study was to evaluate a clinical pharmacy-led multifaceted intervention to improve healthcare professionals' knowledge, attitudes, and reporting practices and to strengthen hospital pharmacovigilance performance. METHODS: We conducted a multicenter pre-post evaluation in three provincial hospitals in Ca Mau province, Vietnam (January 1, 2022-June 30, 2025). Repeated cross-sectional surveys were administered before and after a 6-month intervention (July-December 2023) (n = 372 each round). All spontaneous ADR reports submitted to the national pharmacovigilance center and archived at hospital pharmacies were retrospectively reviewed. Report completeness was assessed using VigiGrade (well documented ≥ 0.8), and organizational capacity was assessed using the Indicator-based Pharmacovigilance Assessment Tool (IPAT). RESULTS: Adequate knowledge increased from 2.7% (10/372) preintervention to 29.8% (111/372) postintervention. Adequate attitudes increased from 57.5% to 64.2%, and adequate self-reported practices from 47.8% to 55.6%. Among professionals who had encountered suspected ADRs, ever-reporting increased from 46/308 (14.9%) to 75/334 (22.5%) (p = 0.015). Spontaneous ADR reports increased from 26 preintervention to 144 postintervention while maintaining high completeness (VigiGrade ≥ 0.8: 96.2% vs. 97.9%; p = 0.419). IPAT performance improved across domains, with the largest gains in monitoring and reporting activities. CONCLUSIONS: A pragmatic, pharmacy-coordinated multifaceted intervention was associated with increased ADR reporting participation and volume without compromising documentation completeness and with strengthened organizational pharmacovigilance performance. This model appears feasible for resource-limited provincial hospitals, but the outcomes should be interpreted as improvements in reporting processes rather than direct evidence of reduced patient harm.

متن کامل اصلی

متن در JumpToDate ذخیره نشده است.

برای بررسی دسترسی کتابخانه‌ای یا خرید، رکورد اصلی را باز کنید.

رفتن به منبع اصلی

کلیدواژه‌ها

adverse drug reactionmedication safetypharmacovigilancepharmacy
در همین زیرشاخه

مقاله‌های مرتبط

PubMed2026

Flibanserin safety in real-world use: a decade of US Food and Drug Administration Adverse Event Reporting System pharmacovigilance evidence.

BACKGROUND: Flibanserin, a centrally acting 5-HT1A agonist and 5-HT2A antagonist, is the first approved therapy for acquired, generalized hypoactive sexual desire disorder in premenopausal women. Despite its clinical availability, post-marketing data on real-world safety remain limited. METHODS: A retrospective pharmacovigilance analysis was conducted using the US Food and Drug Administration Adverse Event Reporting System from 2016 to…

PubMed2026

Risk of Major Malformations Following First-Trimester Exposure to Cariprazine: Preliminary Data From the MGH National Pregnancy Registry for Psychiatric Medications.

OBJECTIVE: Systematically collected pregnancy safety data for cariprazine have been lacking, despite growing use of this medication across psychiatric indications. The goal of this analysis was to determine the risk of major malformations among infants of mothers with psychiatric illness who used cariprazine during the first trimester of pregnancy compared to unexposed controls. METHODS: The National Pregnancy Registry for Psychiatric …

PubMed2026

Using Pharmacovigilance Data for Signal Detection of Drug Interactions for Rosuvastatin.

The 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitor rosuvastatin is a substrate of breast cancer resistance protein (BCRP). BCRP inhibition increases rosuvastatin plasma concentrations and may result in concentration-dependent muscle toxicity, at worst rhabdomyolysis. We investigated if concomitant use of rosuvastatin and drugs identified as in vitro BCRP inhibitors shows an increased number of rhabdomyolysis events based on…

PubMed2026

Assessing the risk of cataracts associated with medications: A pharmacovigilance analysis of the FAERS database.

Cataracts are a leading cause of global blindness and visual impairment, with drug-induced cataracts emerging as a significant yet understudied contributor. This study aimed to comprehensively and systematically investigate medication-related cataract risk signals using data from the FDA Adverse Event Reporting System. We searched the FDA Adverse Event Reporting System database for all reported cases of medication-related cataracts fro…